The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma
Authors:
- 23 May 2011
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (10) , 1857-1866
Abstract
The mammalian target of rapamycin (mTOR) is centrally located, linking proximal oncogenic cascades to critical downstream pathways that drive tumor growth. mTOR regulates such diverse functions as protein translation, proliferation, viability, autophagy, metabolism homeostasis, monitoring of energy reserves, and induction of angiogenesis. Given its fundamental role in tumorigenesis, it is not surprising that a huge effort is being made to develop mTOR inhibitors. The existence of feedback pathways that become activated subsequent to mTOR inhibition has complicated these efforts. However, the fact that mTOR exists in two separate complexes, TORC1 and TORC2, and rapalogs primarily inhibit only TORC1 and TORC2 is actually a key activator of AKT, has injected new energy into the quest to find inhibitors that can inhibit both complexes. In myeloma models, preclinical studies confirm the activity of rapalogs as well as newer TORC1/TORC2 inhibitors, and early phase clinical trials have begun. In addition, the recent finding of up-regulated myeloma cell expression of DEPTOR, an mTOR binding protein that restricts mTOR activity, suggests an additional future therapeutic target specific to the myeloma tumor model.Keywords
This publication has 64 references indexed in Scilit:
- Amino Acids Activate Mammalian Target of Rapamycin Complex 2 (mTORC2) via PI3K/Akt SignalingJournal of Biological Chemistry, 2011
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple MyelomaMolecular Cancer Therapeutics, 2010
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4ECancer Cell, 2010
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycinMolecular Cancer Therapeutics, 2009
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991